<code id='0E983E4AC0'></code><style id='0E983E4AC0'></style>
    • <acronym id='0E983E4AC0'></acronym>
      <center id='0E983E4AC0'><center id='0E983E4AC0'><tfoot id='0E983E4AC0'></tfoot></center><abbr id='0E983E4AC0'><dir id='0E983E4AC0'><tfoot id='0E983E4AC0'></tfoot><noframes id='0E983E4AC0'>

    • <optgroup id='0E983E4AC0'><strike id='0E983E4AC0'><sup id='0E983E4AC0'></sup></strike><code id='0E983E4AC0'></code></optgroup>
        1. <b id='0E983E4AC0'><label id='0E983E4AC0'><select id='0E983E4AC0'><dt id='0E983E4AC0'><span id='0E983E4AC0'></span></dt></select></label></b><u id='0E983E4AC0'></u>
          <i id='0E983E4AC0'><strike id='0E983E4AC0'><tt id='0E983E4AC0'><pre id='0E983E4AC0'></pre></tt></strike></i>

          Home / knowledge / knowledge

          knowledge


          knowledge

          author:focus    Page View:11

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In